Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease

Lancet

Volumn 351, Issue 9105, 1998, Pages 773-780

  Paggiaro, Pier Luigi ^a   Dahle, Ragnar ^b   Bakran, Ivan ^c   Frith, Lucy ^d   Hollingworth, Kate ^d   Efthimiou, John ^d  

^a UNIVERSITY OF PISA   (Italy)

^b Ostfold Central Hospital   (Norway)

^c UNIVERSITY HOSPITAL OSIJEK   (Croatia)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; FLUTICASONE PROPIONATE; HYDROCORTISONE; PLACEBO; SALBUTAMOL;

ADULT; AGED; ARTICLE; CANDIDIASIS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DYSPHONIA; EUROPE; FEMALE; FORCED EXPIRATORY VOLUME; HOARSENESS; HUMAN; HYDROCORTISONE BLOOD LEVEL; INHALATIONAL DRUG ADMINISTRATION; INHALER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEW ZEALAND; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; SOUTH AFRICA; SPUTUM;

EID: 0032515756     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)03471-5     Document Type: Article

References (32)

1. 1 Fletcher CM, Pride NM. Definitions of emphysema, chronic bronchitis, asthma, and airflow obstruction: 25 years on from the Ciba symposium. Thorax 1984; 39: 81-85.
2. 2 Fletcher CM, Peto R. The natural history of chronic airflow obstruction. BMJ 1978; 1: 1645-48.
3. 3 Thorn TJ. International comparisons in COPD mortality. Am Rev Respir Dis 1989; 140: 27-34.
4. 4 Humbert M. Airways inflammation in asthma and chronic bronchitis. Clin Exp Allergy 1996; 25: 735-37.
5. 5 Siafakas NM, Vermiere P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): European Respiratory Society consensus statement. Eur Respir J 1995; 8: 1398-420.
6. 6 Engel T, Heining JH, Madson O, Hanson M, Weeks ER. A trial of inhaled budesonide on airways responsiveness in smokers with chronic bronchitis. Eur Respir J 1989; 2: 935-39.
7. 7 Auffarth B, Postma DS, DeMonchy JGR, Van der Mark TW, Boorsma M, Koeter GH. Effects of inhaled budesonide on spirometry, reversibility, airway responsiveness and cough threshold in smokers with COPD. Thorax 1991; 46: 327.
8. 8 Weir DC, Gove RI, Robertson AJ, Burge SP. Corticosteroid trials in non-asthmatic chronic airflow obstruction. Thorax 1990; 45: 112-17.
9. 9 Pride NB, Taylor RG, Lins H, Joyce H, Watson A. Bronchial hyper-responsiveness as a risk factor for progressive airflow obstruction in smokers. Bull Eur Physiopathol Respir 1987; 23: 369-75.
10. 10 Dompeling E, van Schayck CP, van Grunsven PM, et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids: a 4-year prospective study. Ann Intern Med 1993; 118: 770-78.
11. 11 Kerstjens HAM, Brand PLP, Hughes MD, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N Engl J Med 1992; 327: 1413-19.
12. 12 Fabbri L, Burge PS, Croonenborgh L, et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax 1993; 48: 817-23.
13. 13 Leblanc P, Mink S, Keistinen T, Saarehuian PA, Ringdal N, Payne SL. A comparison of fluticasone propionate 200 μg/day with beclomethasone dipropionate 400 μg/day in adult asthma. Allergy 1994; 49: 380-85.
14. 14 Barnes NC, Marone G, DiMaria GU, Visser S, Utama I, Payne SL. A comparison of fluticasone propionate 1 mg daily, with beclomethasone dipropionate, 2 mg daily in the treatment of severe asthma. Eur Respir J 1993; 6: 877-84.
15. 15 Noonan M, Chervinsky P, Busse WW, et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 1995; 152: 1467-73.
16. 16 Ayres JG, Bateman ED, Lundback B, Harris TAJ. High dose fluticasone propionate 1 mg daily versus 2 mg daily, or budesonide 1·6 mg daily in patients with chronic severe asthma. Eur Respir J 1995; 8: 579-86.
17. 17 Barnes NC, Hallett C, Harris TAJ. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone propionate at half the microgram dose or less. Respir Med 1998; 92: 95-104.
18. 18 Llewellyn-Jones CG, Harris TAJ, Stockley RA. The effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996; 153: 616-21.
19. 19 Wilson RC, Jones PW. Long-term reproducibility of Borg scale estimates of breathlessness during exercise. Clin Sci 1991; 80: 309-12.
20. 20 Peace KE, ed. Biopharmaceutical statistics for drug development. New York: Marcel Dekker, 1988: 403-57.
21. 21 van Elteren PH. On the combination of independent two sample tests of Wilcoxon. Bull Int Stat Inst 1960; 37: 351-61.
22. 22 Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815-21.
23. 23 Callahan C, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 1993; 118: 770-78.
24. 24 Rutten-van Mölken MPMA, Jansen MCC, van Doorslaer EKA, et al. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and COPD. Am J Respir Crit Care Med 1995; 151: 975-82.
25. 25 Keatings VM, Jatakanon A, Worsdell YM, Barnes P. Effects of inhaled oral glucocorticoids in inflammatory indices in asthma and COPD. Am J Resp Crit Care Med 1997; 155: 542-48.
26. 26 Renkema TEJ, Schouten JP, Koeter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest 1996; 109: 1156-62.
27. 27 Weiner P, Weiner M, Azgad Y, Zamir D. Inhaled budesonide therapy for patients with stable COPD. Chest 1995; 108: 1568-71.
28. 28 Thompson AB, Mueller MB, Heires AJ, et al. Aerosolised beclomethasone in chronic bronchitis: improved pulmonary function and diminished airway inflammation. Am Rev Respir Dis 1992; 146: 389-95.
29. 29 Chanez P, Vignola AM, O'Shaugnessy T, et al. Corticosteroid therapy in COPD is related to features of asthma. Am J Respir Crit Care Med 1997; 155: 1529-34.
30. 30 van Schayck CP, van Grusven PM, Dekhuijzen PNR. Do patients with COPD benefit from treatment with inhaled corticosteroids? Eur Respir J 1996; 9: 1969-72.
31. 31 Pauwels RA, Lofdahl CG, Pride NB, Postma DS, Laitinen LA, Ohlsson SV. European Respiratory Society study on chronic obstructive pulmonary disease (Euroscop): hypothesis and design. Eur Respir J 1992; 5: 1254-61.
32. 32 Burge PS, Calverley PMA, Daniels JE. The acute effects of oral prednisolone in patients with COPD in the ISOLDE trial: responders and non-responders? Am J Respir Crit Care Med 1996; 153: 126.